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Nephrotic syndrome is recognized as a significant cardio-vascular disease (CVD) risk factor, associated with hyper-
tension and accelerated atherosclerosis. In fact, the American 
Heart Association classifies nephrotic syndrome in children as 
a Tier II CVD risk factor.1 Primary glomerular diseases such as 
membranous nephropathy, focal segmental glomerulosclerosis 
(FSGS), and minimal change disease (MCD) often become 
manifest in individuals when nephrotic syndrome develops, 
and treatment focuses on decreasing proteinuria and inducing 
remission. The clinical course of these diseases can include 
periods of remission and relapse of nephrotic syndrome. 
Hypertension and CVD are comorbid conditions associated 
with these entities.
While not completely understood, there are several pos-
sible pathophysiologic mechanisms for the development of 
elevated blood pressure (BP) and hypertension among indi-
viduals with primary proteinuric glomerulopathies. Proposed 
causes include renin–angiotensin–aldosterone system (RAAS) 
activation, sodium retention, and volume expansion either 
because of RAAS activation or secondary to a sodium-han-
dling defect.2 Elevated BP is also caused by medication side 
effects of corticosteroids and calcineurin inhibitors (CNIs) 
that are commonly used in the treatment of individuals with 
proteinuric disease. Despite the increased risk for CVD mor-
bidity and mortality among these individuals, the prevalence 
of hypertension, antihypertensive treatment patterns, and rela-
tionship of hypertension to clinical outcomes in these specific 
glomerular diseases have not been well described.
Independent of adequate BP control, visit-to-visit BP 
variability (BPV), defined as the degree of variation between 
discrete BP readings at separate time points, has been shown 
to predict cardiovascular morbidity and mortality in the gen-
eral population and in patients with chronic kidney disease.3–6 
In addition, greater visit-to-visit BPV has been associated 
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with worse proteinuria and renal function.7,8 The relationship 
between visit-to-visit BPV and renal outcomes in proteinuric 
glomerular disease is unknown.
To characterize CVD risk factors and antihypertensive 
treatment patterns among a contemporary cohort of adults 
and children with primary glomerular diseases that can pres-
ent with nephrotic syndrome, we studied individuals enrolled 
in the NEPTUNE (Nephrotic Syndrome Study Network). 
The goals of this study were (1) to define the prevalence 
and management of hypertensive BP status in patients with 
primary proteinuric glomerulopathies across age groups and 
histological diagnoses and (2) to determine whether hyper-
tensive BP status and BPV were associated with adverse 
renal outcomes.
Materials and Methods
NEPTUNE (Nephrotic Syndrome Study Network)
The design of the NEPTUNE study has been previously described 
in detail.9 In brief, NEPTUNE is a multicenter observational cohort 
study of children and adults with glomerular diseases that cause 
nephrotic syndrome. Participants of any age with ≥500 mg/d of pro-
teinuria on a 24-hour urine sample or with a urine protein/creatinine 
ratio ≥0.5 g/g on a spot urine specimen were enrolled at the time 
of a clinically indicated kidney biopsy at 21 sites in North America. 
Patients with kidney manifestations of systemic disease, prior solid 
organ transplant, or life expectancy <6 months were excluded. There 
were 470 participants enrolled between July 1, 2010 and May 1, 2016. 
Participants were assigned to the following disease cohorts based on 
histological confirmation by core pathologists: MCD, FSGS, mem-
branous nephropathy, or other glomerulopathy, which included IgA 
nephropathy.10 Study visits consisted of data and biosample collec-
tion at baseline, every 4 months during the first year, and then every 6 
months for a total of 5 years. The study protocol was approved by the 
Institutional Review Board at each participating site, and informed 
consent/assent was obtained from each participant.
BP Measurements
Casual BP measurements were obtained in triplicate at each study 
visit using a calibrated oscillometric device. BP was measured in the 
right arm with the participant in a seated position after 5 minutes of 
rest. The average of the last 2 readings was used. Participants were 
classified as hypertensive BP status (HTN) if either of the follow-
ing criteria were met: (1) a clinical diagnosis of hypertension was 
recorded in their medical record or (2) their average baseline BP was 
in the hypertensive range for age. Among the subset of individuals 
categorized as HTN who had a previous clinical diagnosis of hyper-
tension, those with an average baseline BP either ≥95th percentile 
for age, sex, and height11 for children or ≥140 mm Hg systolic or ≥90 
mm Hg diastolic12 for adults were consider to be hypertensive uncon-
trolled. Those with a clinical diagnosis of hypertension with BPs 
below these thresholds were considered hypertensive controlled. To 
allow for comparison across adults and children, a systolic and dia-
stolic BP index was calculated: average measured BP was divided by 
140 or 90 as applicable in adults or by the sex-, age-, and height-spe-
cific 95th percentile BP in children. Although BP index has not been 
used previously in adult studies, BP index is a common approach to 
standardize BP among individuals of different age, sex, and size in 
the pediatric literature.13–15 BP index ≥1 indicates BP in the hyperten-
sive range, and every 0.1 U increase represents a 10% increase in BP 
above hypertensive range.
Visit-to-visit BPV was calculated using BP measurements obtained 
during the first year of the study in participants with ≥3 separate visits 
with a documented BP measurement. We chose to examine 2 metrics 
of systolic and diastolic BPV: (1) SD which measures overall vari-
ability and (2) average real variability (ARV) which measures vari-
ability between consecutive visits and was calculated as the mean 
difference in BP between visits.16
CVD Risk Factors, Covariate, and Outcome 
Measurements
Clinical and demographic characteristics, including immunosuppres-
sive and antihypertensive medication use, urine protein/creatinine 
ratio, serum creatinine, and self-reported smoking status, were col-
lected from the participants. Children <18 years old were catego-
rized into the pediatric group; all others were categorized as adults. 
Weight status was classified into normal, overweight, and obese 
categories based on reference data for body mass index in adults or 
body mass index percentile in children.17 The presence of edema was 
documented by a clinician at each study visit. Estimated glomeru-
lar filtration rate (eGFR) was calculated using the Chronic Kidney 
Disease–Epidemiology (CKD-Epi) formula for participants ≥18 years 
and the modified Schwartz formula for participants <18 years.18,19
Renal outcomes that were pre-determined by NEPTUNE includ-
ed complete remission ever, composite end point, and eGFR slope. 
Complete remission ever was defined as urine protein/creatinine ra-
tio ≤0.3 at any study visit. The composite end point was defined as 
development of end-stage renal disease (ESRD) or eGFR decline by 
≥40% by the time of the last follow-up. The eGFR slope of the least-
squares regression line was calculated for each person using the first 
and last serum creatinine measured at least 8 months apart, reported 
as mL min−1 y−1.
Statistical Analysis
NEPTUNE participants with BP recorded at the baseline visit were 
included in this analysis. Adult and pediatric patients were consid-
ered separately and then compared. Descriptive statistics were used 
to describe the demographic and clinical characteristics among the 
full cohort, stratified by age and histological subgroups based on 
χ2/Fisher exact tests or the Wilcoxon rank-sum/Kruskal–Wallis test 
for categorical and continuous variables, respectively. Multivariable 
logistic regression was used to evaluate the association of disease 
cohort and odds of having HTN for both adults and children adjusting 
for age, sex, race, weight status (overweight/obese versus not), edema 
(yes/no), steroid use (yes/no), CNI use (yes/no), eGFR, and smoking 
status (yes/no; adults only).
To evaluate the association of renal outcomes (eGFR slope, com-
posite end point, and complete remission ever) with HTN and BPV, 
regression models were used adjusting for age, sex, race, disease co-
hort, and follow-up time (model 1). A second model (model 2) in-
cluded those variables from model 1 in addition to smoking status, 
CNI/steroid use, RAAS use, weight status, edema, cholesterol, and 
baseline systolic BP index and baseline eGFR. Multiple linear re-
gression based on generalized estimating equations to account for the 
correlation of individual-level clinical visits was used to determine 
the relationship between HTN and BPV with eGFR slope. Finally, 
pooled logistic regression models with a complementary log–log link 
were used to evaluate the association of HTN and BPV with time 
to complete remission ever and the composite end point. Results of 
these analyses are presented as hazard ratios with corresponding 95% 
confidence interval (CI). The time-to-event analysis started with the 
baseline visit. The entire follow-up period was used to analyze out-
comes where HTN was the primary exposure of interest, whereas a 
minimum of 2 visits after year 1 in participants was included in the 
outcome analysis for BPV only. All analyses were conducted using 
SPSS, version 24 (IBM Inc) and R version 3.3.2.20 A 2-sided P value 
of ≤0.05 was considered statistically significant.
Results
Patient Population
There were 443 participants with baseline BP, including 296 
adults and 147 children enrolled in NEPTUNE as of May 
1, 2016. Cross-sectional baseline demographic and clinical 
characteristics of the study cohort stratified by age group 
are summarized in Table 1. There was a significantly greater 
proportion of black race and lower prevalence of obese/
overweight in the pediatric group. Diagnosis differed by 
age group; there was a higher proportion of membranous 
nephropathy in adults and a higher proportion of MCD in 
children. Children had a significantly higher eGFR and lower 
urine protein/creatinine ratio than adults. The pediatric group 
also had a significantly greater proportion of participants 
Table 1. Demographics and BP of the NEPTUNE (Nephrotic Syndrome Study Network) Cohort 
at Baseline
Characteristics, n (%) or Median (IQR) Adult, n=296 Pediatric, n=147 P Value
Age, y 43 (32–57.8) 11 (5–14) <0.0001
Male 182 (61.5%) 85 (57.8%) 0.46
Black 61 (21.3%) 61 (43.9%) <0.0001
Hispanic 62 (20.9%) 33 (22.4%) 0.82
BMI, kg/m2 28.4 (24.8–33.2) 20.8 (17.7–24.9) <0.0001
Obese/overweight 217 (73.3%) 84 (57.1%) 0.003
Edema 133 (44.9%) 55 (37.4%) 0.13
Smoker 31 (10.5%) 1 (0.7%) 0.001
Disease duration, mo 12 (0–24) 12 (0–12) 0.73
Follow-up time, mo 24.5 (12–37) 24 (12–36) 0.49
Cohort: MCD 40 (13.2%) 69 (46.9%) <0.0001
 MN 71 (24%) 2 (1.4%)
 FSGS 98 (33.1%) 49 (33.3%)
 IgA 48 (16.2%) 8 (5.4%)
 Other* 39 (13.2%) 19 (12.9%)
Hypertensive BP status† 192 (64.8%) 69 (46.9%) <0.0001
Hypertensive uncontrolled† 69 (23.3%) 61 (41.5%) <0.0001
SBP, mm Hg 124 (113–137) 109 (101–118) <0.0001
DBP, mm Hg 77.5 (69–85) 68 (61–77) <0.0001
SBP index‡ 0.89 (0.81–0.98) 0.92 (0.87–1.0) <0.0001
DBP index‡ 0.86 (0.77–0.94) 0.90 (0.81–1.0) <0.0001
SBP SD, mm Hg 10 (6.6–14.7) 7.3 (4.5–10.2) <0.0001
DBP SD, mm Hg 6.5 (4.3–9.7) 7.1 (4.2–10.7) 0.34
SBP ARV, mm Hg 11.7 (7–18) 8.0 (5.5–11.8) <0.0001
DBP ARV, mm Hg 8 (5–11.3) 8 (5.5–12.2) 0.38
No antihypertensive medication 36 (12.1%) 64 (43.5%) <0.001
1 antihypertensive medication 93 (31.4%) 64 (43.5%)
2 antihypertensive medications 101 (34.1%) 15 (10.2%)
≥3 antihypertensive medications 66 (22.2%) 4 (2.7%)
Steroid use 74 (25%) 102 (69.4%) <0.0001
CNI use 9 (3%) 39 (26.5%) <0.0001
eGFR, mL min−1 1.73 m−2 69.5 (42.6–96.3) 100.4 (82–118.3) <0.0001
UPC, g/g 2.3 (0.86–4.1) 1.2 (0.22–4.1) 0.005
ARV indicates average real variability; BMI, body mass index; BP, blood pressure at baseline; CNI, calcineurin inhibitor; DBP, 
diastolic BP; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; IQR, interquartile range; 
MCD, minimal change disease; MN, membranous nephropathy; SBP, systolic BP; and UPC, urine protein:creatinine ratio.
*Other glomerulopathy cohort included diagnoses of membranoproliferative glomerulonephritis, thin basement
membrane, complement 1Q, complement 3 glomerulopathy, crescentic glomerulonephritis, mesangial, glomerulosclerosis, 
membranous with nodular diabetes mellitus, nodular glomerulosclerosis, thrombotic microangiopathy, and indeterminate.
†Hypertensive BP status defined as previous clinical diagnosis of hypertension or an elevated BP for age at the baseline 
visit; hypertensive uncontrolled defined as previous diagnosis of hypertension and elevated BP at the baseline visit.
‡BP index: BP was divided by 140 or 90 in adults or by the 95th percentile BP in children; an index ≥1 is indicative of a 
BP in the hypertensive range.
treated with steroids and CNI than the adult group. For the 
entire cohort, the median follow-up time was 24 months 
(interquartile range, 12–37 months) with a median of 4 visits 
(interquartile range, 2–7 visits; 13.8% with 3 visits, 11% with 
4 visits, 10% with 5 visits, 9.6% with 6 visits, and 27.9% with 
≥7 visits). There was no difference in mean follow-up time 
between age groups.
Hypertensive BP Status
At baseline, 261 participants (58.9%) had a previous clini-
cal diagnosis of hypertension (n=207) or had baseline BP 
in the hypertensive range (n=54) and were classified as 
HTN. Children were disproportionately more likely to be 
categorized as HTN based on baseline BP than by previous 
clinical diagnosis of hypertension, 59.4% (n=41/69) versus 
40.6% (n=28/69), P=0.001, respectively. Although HTN was 
more prevalent among adults than children, children were 
more likely to be categorized as hypertensive uncontrolled 
(Table 1).
Comparing by disease cohort, there was a significant 
difference in prevalence of HTN across the disease groups 
in adults but not in children (Table 2). Disease cohort was 
significantly associated with HTN after adjustment for age, 
sex, race, weight status, edema, steroids, CNI, eGFR, and 
smoking (adults) in adults (P=0.036) but not in children 
(P=0.9). For adults, the odds of HTN were 5.5× greater 
in IgA and 3.8× greater in FSGS compared with MCD 
(Table 3).
Table 2. BP, BP Variability, and Hypertension Risk Factors by Disease Cohort
Characteristics, n (%) or Median (IQR) MCD MN FSGS IgA P Value
Adult n=40 n=71 n=98 n=48
 Hypertensive BP status* 16 (40%) 46 (64.8%) 73 (74.5%) 34 (70.8%) 0.004
 Hypertensive uncontrolled* 4 (7.1%) 9 (16.1%) 26 (46.4%) 10 (17.9%) 0.1
 SBP, mm Hg 121 (107.3–129) 121 (113–135) 125 (115–137.3) 126 (115.3–139.5) 0.33
 DBP, mm Hg 74.5 (65–81.8) 77 (69–84) 80 (69.8–88) 78 (73–85.8) 0.11
 SBP SD, mm Hg 7.1 (4.9–12.4) 11.1 (7.1–16.4) 11 (6.9–15.8) 8.8 (6.9–12.2) 0.19
 DBP SD, mm Hg 7 (3.4–8.9) 6.5 (4.2–9.4) 7.1 (5.2–9.7) 6.3 (4.3–10.8) 0.47
 SBP ARV, mm Hg 9 (5.3–17) 13.5 (7.2–18) 12.8 (8.3–20.8) 11.2 (7.3–17.4) 0.52
 DBP ARV, mm Hg 6.3 (2.7–10) 7.7 (4.3–10.8) 8.6 (5.9–12.5) 7.2 (5.3–13.8) 0.11
 Steroid use 19 (47.5%) 10 (14.1%) 16 (16.4%) 17 (35.4%) 0.001
 CNI use 3 (7.5%) 4 (5.6%) 0 (0%) 0 (0%) 0.13
 eGFR, mL min−1 1.73 m−2) 85.9 (45.9–107) 81.4 (65.2–98.2) 52 (33.9–82.4) 62.2 (36.9–95.3) <0.0001
 UPC, g/g 0.78 (0.1–3.3) 4.3 (2.5–7.2) 2.2 (0.97–3.5) 1.4 (0.6–3.0) <0.0001
Pediatric n=69 n=2 n=49 n=8
 Hypertensive BP status* 31 (44.9%) 1 (50%) 23 (46.9%) 5 (62.5%) 0.91
 Hypertensive uncontrolled* 9 (45%) 1 (50%) 6 (12.2%) 2 (10%) 0.5
 SBP (mm Hg)† 107 (100–116) 121.5 112 (102–118.5) 124.5 (105–133) 0.13
 DBP (mm Hg)† 66 (60–74.5) 77.5 71 (61–77) 70 (63.8–80.3) 0.56
 SBP index 0.92 (0.87–1.0) 0.97 0.90 (0.85–0.99) 1.0 (0.93–1.1) 0.6
 DBP index 0.91 (0.80–1.0) 0.96 0.90 (0.79–1.0) 0.88 (0.84–1.0) 0.84
 SBP SD (mm Hg) 6.4 (3.6–9.4) 9.6 7.1 (5–10.4) 8.3 (5.6–12.7) 0.41
 DBP SD mm Hg) 6.5 (4.2–9.9) 8.9 7.1 (4.1–12.5) 7 (3–9.4) 0.78
 SBP ARV (mm Hg) 7 (4–11) 9.5 9 (6–11.9) 9.1 (6.6–11.8) 0.28
 DBP ARV (mm Hg) 98 (5–11.2) 9 8.4 (6–14.4) 7.8 (3.9–9.1) 0.49
 Steroid use 49 (71%) 1 (50%) 34 (69.4%) 3 (37.5%) 0.02
 CNI use 18 (26.1%) 1 (50%) 16 (32.7%) 2 (25%) 0.4
 eGFR, mL min−1 1.73 m−2 110.4 (92–133) 118.3 89.5 (77–110.7) 65.6 (55.8–98.9) <0.0001
 UPC, g/g 0.39 (0.1–4.2) 2.3 2.4 (0.68–5.9) 1.2 (0.17–5.0) 0.34
ARV indicates average real variability; BP, blood pressure at baseline; CNI, calcineurin inhibitor; DBP, diastolic BP; eGFR, estimated glomerular filtration rate; 
FSGS, focal segmental glomerulosclerosis; IQR, interquartile range; MCD, minimal change disease; MN, membranous nephropathy; SBP, systolic BP; and UPC, urine 
protein:creatinine ratio.
*Hypertensive BP status defined as previous diagnosis of hypertension or elevated BP for age at the baseline visit; hypertensive uncontrolled defined as previous
diagnosis of hypertension and elevated BP at the baseline visit.
†SBP/DBP index: BP was divided by the 95th percentile BP in children.
Treatment Patterns
Antihypertensive treatment by age group is shown in Table 
S1 in the online-only Data Supplement. In contrast to adults, 
children more frequently were not treated with antihyperten-
sive medications (43.5% versus 12.1%) at baseline (P<0.001). 
Overall, RAAS blockade (65.1%) was most common fol-
lowed by diuretics (35.7%) and calcium channel blockers 
(22.2%). A greater proportion of adults were taking each class 
of antihypertensive medication when compared with children 
(all P<0.05).
Blood Pressure Variability
There were 378 (85.3%) participants with ≥3 BP readings 
over separate visits during the first year of participation in 
NEPTUNE from which visit-to-visit BPV was calculated. 
Adults had significantly greater systolic SD and ARV com-
pared with children (Table 1). There was no significant differ-
ence in these parameters by disease cohort (Table 2).
Variables were assessed in regression models to examine 
determinants of BPV in adults and children. In adults, black 
race (β=2.8; 95% CI, 0.65–4.9; P=0.01) and baseline systolic 
BP (β=0.08; 95% CI, 0.03–0.13; P=0.004) were significantly 
associated with systolic SD in the multivariable model adjust-
ing for age, sex, race, weight status, and edema. Black race 
was also associated with systolic ARV in adults (β=3.6; 95% 
CI, 0.67–6.6; P=0.02). In children, baseline systolic BP was 
directly related to systolic SD (β=0.23; 95% CI, 0.15–0.3; 
P<0.0001) and systolic ARV (β=0.2; 95% CI, 0.12–0.3; 
P<0.0001). Disease cohort, antihypertensive medication class, 
immunosuppression, weight status, and edema were not asso-
ciated with BPV in adults or children.
Hypertensive BP Status and BPV with Outcomes
Overall, after a median of 2 years of follow-up, there were 212 
complete remission ever events (129/296 in adults and 83/147 
in children) and 91 composite end point events (69/296 in 
adults and 22/147 in children).
In adults, HTN was significantly associated with a lower 
hazard of complete remission ever (P<0.001) in models 1 
and 2 (Table 4; Figure S1). HTN was also associated with a 
4.1× greater hazard of reaching the composite end point only 
in the more parsimonious model 1 (Figure). There was no 
Table 3. Adjusted ORs of Baseline Hypertensive Blood 




OR (95% CI) P Value OR (95% CI) P Value
MCD Ref Ref
MN 1.8 (0.62–5) 0.29 … …
FSGS 3.8 (1.4–10.9) 0.01 0.86 (0.35–2.1) 0.73
IgA 5.5 (1.7–18) 0.005 1.8 (0.3–10) 0.53
Other 2.3 (0.68–7.5) 0.18 0.7 (0.2–2.5) 0.59
Model adjusted for age, sex, race, weight status, edema, steroids, calcineurin 
inhibitors, estimated glomerular filtration rate, and smoking (adults). MN 
excluded from the pediatric cohort. CI indicates confidence interval; FSGS, 
focal segmental glomerulosclerosis; MCD, minimal change disease; MN, 
membranous nephropathy; and OR, odds ratio.
Table 4. Association of Hypertensive Blood Pressure Status 
at Baseline and Blood Pressure Variability Over the First 
Year with Clinical Outcomes in Adults Enrolled in NEPTUNE 
(Nephrotic Syndrome Study Network)
Outcome β 95% CI P Value
eGFR slope, mL min−1 y−1
 HTN
 Model 1 −0.92 (−3.28 to 1.45) 0.45
 Model 2 2.07 (−2.51 to 6.65) 0.38
 SBP SD
 Model 1 0.06 (−0.1 to 0.22) 0.44
 Model 2 0.08 (−0.08 to 0.23) 0.35
 DBP SD
 Model 1 0.00 (−0.22 to 0.21) 0.98
 Model 2 0.01 (−0.2 to 0.23) 0.91
 SBP ARV
 Model 1 0.04 (−0.09 to 0.18) 0.52
 Model 2 0.05 (−0.08 to 0.19) 0.43
 DBP ARV
 Model 1 −0.06 (−0.24 to 0.13) 0.55
 Model 2 −0.05 (−0.23 to 0.13) 0.61
Complete remission ever 
(UPC <0.3)
HR 95% CI P value
 HTN
 Model 1 0.36 (0.19 to 0.68) <0.001
 Model 2 0.48 (0.29 to 0.80) <0.001
 SBP SD
 Model 1 1.01 (0.98 to 1.04) 0.41
 Model 2 1.03 (0.99 to 1.07) 0.10
 DBP SD
 Model 1 1.01 (0.98 to 1.03) 0.55
 Model 2 1.02 (0.99 to 1.05) 0.13
 SBP ARV
 Model 1 1.00 (0.96 to 1.04) 0.92
 Model 2 1.01 (0.96 to 1.07) 1.01
 DBP ARV
 Model 1 0.98 (0.94 to 1.01) 0.19
 Model 2 0.99 (0.94 to 1.03) 0.55
Composite end point (ESRD or eGFR decline <40%)
 HTN
 Model 1 4.11 (1.41 to 12.02) 0.01
 Model 2 1.40 (0.71 to 2.76) 0.33
 SBP SD*
 Model 1 1.05 (1.02 to 1.09) <0.001
 DBP SD*
 Model 1 1.04 (1.01 to 1.07) 0.01
(Continued )
association of baseline HTN with eGFR slope. Greater sys-
tolic and diastolic BPVs were associated with a greater hazard 
of reaching the composite end point (Table 4). For each 1 U 
increase in systolic SD, there was a 5% increase in the occur-
rence of the composite end point (model 1). For systolic ARV, 
there was a 10% increase in composite end point for each 1 U 
increase (model 1).
In children, HTN trended toward lower hazard of com-
plete remission ever in model 1, but failed to reach statistical 
significance (Table 5). HTN was not associated with eGFR 
slope or composite end point in children. Greater systolic SD 
and ARV were associated with a greater hazard of reaching 
the composite end point in model 1. Systolic and diastolic 
ARV were also associated with a lower hazard of complete 
remission ever in children (Table 5).
Discussion
In this large cohort of adults and children with primary pro-
teinuric glomerulopathies, nearly 60% of participants had 
HTN at enrollment. Although HTN was more prevalent 
among adults, children were more often categorized as hav-
ing uncontrolled BP. Treatment with antihypertensive medi-
cation was common, although less so in children compared 
with adults. Of the various antihypertensive classes, RAAS 
blockade was the most commonly prescribed, with two thirds 
of the population overall treated with these agents. In adults, 
HTN was associated with lower odds of complete remission 
ever and greater hazard of reaching the composite end point 
of ESRD or eGFR decline by ≥40%. Adults had significantly 
greater BPV as determined by systolic SD and ARV when 
compared with children, and these measures, along with dia-
stolic SD and ARV, were associated with a greater hazard of 
reaching the composite end point in adults. In children, BPV 
was also associated with greater hazard of reaching the com-
posite end point (as determined by systolic SD and ARV) and 
with a lower hazard of reaching complete remission ever (as 
determined by systolic and diastolic ARV).
Although nephrotic syndrome is known to be associated 
with increased cardiovascular risk, there is little informa-
tion on the prevalence of hypertension and antihypertensive 
treatment patterns in adults and children with primary pro-
teinuric glomerulopathies associated with nephrotic syn-
drome. We found that HTN was more common in adults than 
in children. In agreement with our findings, a smaller study 
of individuals with FSGS also described a substantial hyper-
tension prevalence: 76% in adults and 44% in children.21 In 
other smaller studies of children, hypertension before corti-
costeroid therapy was reported to be uncommon in MCD but 
was found in 20% to 50% of children with FSGS at the time of 
diagnosis.22,23 Prevalence rates of hypertension as determined 
by 24-hour ambulatory BP monitoring vary in the literature, 
ranging from 14% to 89%.24–26 Our finding of a higher preva-
lence of HTN in adults compared with children could possibly 
be explained by the higher baseline prevalence of essen-
tial hypertension found in the general adult population and 
lower eGFR in adults compared with children in this cohort. 
Surprisingly, we found that disease cohort was not associated 
with HTN in children, whereas FSGS and IgA were determi-
nants of HTN in adults. This finding in children could pos-
sibly be explained by the almost universal use of steroid/CNI 
treatment in children regardless of disease cohort. In addition, 
we observed that BP was treated more aggressively in adults 
than in children. As expected, RAAS blockade was the most 
used class of antihypertensive medications, likely owing its 
antiproteinuric effects.
There is also a paucity of data on the relationship of 
hypertension with clinical outcomes in primary proteinuric 
glomerulopathies. Our findings support our hypothesis that 
HTN is associated with worse clinical outcomes in adults 
with proteinuric glomerulopathies. We demonstrate that 
adult hypertensive BP status is associated both with the 
development of ESRD and with a decline in eGFR of ≥40%. 
Data from the CRIC (Chronic Renal Insufficiency Cohort) 
support that hypertension is associated with progression of 
renal disease and ESRD; however, the cohort includes vari-
ous causes of kidney disease.27 The scant reports on primary 
glomerulopathies are conflicting. Moranne et al28 reported 
that baseline hypertension was not predictive of ESRD in 
those of primary glomerulonephritis, whereas Chou et al29 
showed that baseline hypertension in IgA nephropathy 
(but not in membranous nephropathy or FSGS) was asso-
ciated with progression to ESRD. Interestingly, Zagury et 
al23 showed that hypertension was associated with increased 
risk for developing ESRD in children with steroid-resistant 
nephrotic syndrome. Although this is in contrast to our find-
ings, where we did not find HTN to be associated with poorer 
outcomes in children, it should be noted that the article by 
Zagury et al23 was not an adjusted analyses and was limited 
to children with steroid resistance.
BPV is emerging as an important CVD risk factor, with 
evidence suggesting that it is associated with clinical out-
comes.3–6 Recent literature suggests that visit-to-visit BPV 
also has promise in predicting renal outcomes. In the ALLHAT 
study (Anti-Lipid Lowering Heart Attack Trial) of 21 245 
hypertensive adults, greater visit-to-visit BPV was associated 
with incident ESRD and ≥50% decline in eGFR independent 
of mean BP.5 Yano et al30 described the association of long-
term visit-to-visit BPV with the development of chronic kid-
ney disease in a large Japanese population. A smaller study 
 SBP ARV*
 Model 1 1.10 (1.02 to 1.18) 0.01
 DBP ARV*
 Model 1 1.08 (1.04 to 1.12) <0.001
Model 1 includes age at baseline, sex, race, disease cohort, and follow-
up time. Model 2 includes model 1+smoking status, calcineurin inhibitor/
steroid use, renin–angiotensin–aldosterone system use, weight status, edema, 
cholesterol, SBP index, and eGFR. ARV indicates average real variability; CI, 
confidence interval; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; ESRD, end-stage renal disease; HR, hazard ratio; HTN, 
hypertensive blood pressure status; SBP, systolic blood pressure; and UPC, 
urine protein creatinine.
*Model 2 failed to converge (ie, there was no maximum to the maximum
likelihood function because there were variables in which there were no 
observations for exposure levels among the cases and controls.)
Table 4. Continued
Outcome β 95% CI P Value
also in Japan demonstrated that increased visit-to-visit BPV 
was associated with albuminuria.7 In this study, we provide 
evidence that this association of BPV to renal outcomes can 
be extended to primary glomerulopathy populations through-
out the lifespan. Our findings also demonstrate that adults 
have significantly greater systolic SD and ARV compared 
with children, which is not surprising given that BPV has been 
shown to increase with mean BP and age.31 Interestingly, dis-
ease cohort, clinical characteristics (weight and edema), and 
treatment (antihypertensive medication class and immunosup-
pressive medications) were not associated with BPV in adults 
or children.
There are limitations to this study that should be taken 
into consideration. Ideally, hypertension is defined by the 
measurement of elevated BP from at least 2 (adults) or 3 
(children) separate office visits.11,12 Guidelines further 
recommend that auscultation is the preferred method of BP 
measurement over oscillometry.11 The use of 24-hour ambu-
latory BP monitoring is also increasingly recommended 
for the diagnosis of hypertension.32 In this study, we used 
previous medical history and the average of 2 seated oscil-
lometric BPs from the baseline visit to determine hyper-
tensive BP status. As a result, our findings may be subject 
to BP misclassification. However, if normotensive patients 
were mislabeled as HTN, we would expect to find weaker 
associations of HTN with outcomes. Although available, 
longitudinal measurements of BP in this cohort were not 
used to define hypertension because of the confounding of 
antihypertensive medication use over time that could have 
potentially affected BP. This is particularly relevant for this 
patient population because many are likely prescribed RAAS 
blockade for treatment of proteinuria. Second, although this 
Figure. Kaplan–Meier plot of hypertensive blood pressure status and composite end point (end-stage renal disease or glomerular filtration 
rate decline 40%; A) overall (P=0.02) and among (B) adults (P=0.02) and (C) children (P=0.84) in the NEPTUNE (Nephrotic Syndrome 
Study Network) cohort.
study focuses on the association of baseline hypertension 
and BPV with outcomes, the relationship between BP, pro-
teinuria cause, and renal outcomes may not necessarily be 
causal, especially given the observational nature of the study. 
However, the renal outcomes evaluated were restricted to a 
period after the measurement of BPV. An additional limita-
tion is that treatment with antihypertensive medications was 
not stable throughout the study duration; therefore, greater 
BPV in these patients could be a reflection of changes in BP 
control caused by medications (ie, patients with higher BP at 
study initiation could potentially be those who experienced 
the greatest fall in BP over time, which in turn affects BPV). 
It should be noted though that baseline BP and use of RAAS 
blockade were adjusted for in the regression models for renal 
outcomes. Last, all the NEPTUNE sites are academic centers 
where practices of BP management may differ from nonaca-
demic institutions, thereby possibly affecting the generaliz-
ability of our results.
Perspectives
In summary, HTN is common among the adults and children 
with primary proteinuric glomerular diseases enrolled in 
NEPTUNE. There were significant differences in the preva-
lence of HTN, BPV, and treatment by age and disease cohort. 
HTN and greater BPV were associated with poorer renal out-
comes, which may have clinical implications. These observa-
tions highlight the importance of further research, including 
clinical trials, to determine the impact of improved BP control 
on renal and CVD outcomes among individuals with primary 
proteinuric glomerular disease.
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What Is New?
• Nephrotic syndrome is recognized as a significant cardiovascular dis-
ease risk factor; however, the prevalence of hypertension and blood
pressure (BP) variability in primary glomerulopathies associated with
nephrotic syndrome have not been well described.
• The relationship of BP and BP variability with renal outcomes in primary
proteinuric glomerular diseases is not known.
What Is Relevant?
• This study describes hypertension and BP variability in adults and chil-
dren with primary proteinuric glomerulopathies.
Summary
In adults and children with primary glomerulopathies associated 
with nephrotic syndrome, nearly 60% of participants had HTN at 
enrollment. Differences in hypertensive status prevalence, BP vari-
ability, and treatment were found by age and histological diagnosis. 
Hypertensive status and greater BP variability were associated with 
poorer clinical outcomes.
Novelty and Significance
